Iris Research Development LLC — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$175,237	17
2024	Research	$109,673	3
2023	Research	$568,362	6
2022	Research	$479,048	4
2021	Research	$10,154	1

Breakdown

Who paid Research payments · program years 2021–2025

Horizon Therapeutics plc $1,057,564 11 payments
Amgen Inc. $170,748 5 payments
Takeda Pharmaceuticals U.S.A., Inc. $114,163 15 payments

Studies the money was for Research payments · program years 2021–2025

A Phase 1B, Combined Single-Dose and Multiple-Dose, Multicenter, Randomized, Open-Label Trial to Assess Safety and Tolerability of Two Different Dose Levels of Subcutaneous Pegloticase in Subjects With Uncontrolled Gout Receiving Methotrexate $446,826 2 payments
A Phase 4, Open-Label Study of Krystexxa (Pegloticase) Co-Administered With Methotrexate (MTX) in Patients With Uncontrolled Gout $222,683 1 payment
Infusion Duration Study to Assess Tolerability of Pegloticase Administered With A Shorter Infusion Duration in Subjects With Uncontrolled Gout Receiving Methotrexate $213,616 1 payment
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Vib7734 for the Treatment of Moderate to Severely Active Systemic Lupus Erythematosus $71,666 2 payments
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) $66,973 11 payments
A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Hzn-825 in Patients With Diffuse Cutaneous Systemic Sclerosis $62,702 2 payments
P2b HZN-825-301 dcSSc BEACON $57,970 1 payment
A Multi-Center, Randomized, Double-Blind, and Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior Biologic Use (LATITUDE-PsA-3002 $47,190 4 payments
P2b HZN-825-302 dcSSc BEACON OLE $44,489 1 payment
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of HZN-1116 in Participants With Sjgren's Syndrome $42,134 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.